{"filing":{"accession_number":"0001193125-26-380171","cik":"0001657677","ticker":"PBLS","company_name":"Parabilis Medicines, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-28","primary_document":"ck0001657677-20260828.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526380171/ck0001657677-20260828.htm"},"events":[{"id":31281,"run_id":28696,"accession_number":"0001193125-26-380171","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Dr. Fawzi Benzaghou, the Company's Chief Medical Officer, is departing effective September 30, 2026, pursuant to a mutual agreement. While the disclosure mentions severance benefits, the principal disclosed action is the departure of a named executive officer from a key leadership position (CMO), making this an exec_departure event. The departure of a CMO at a biopharmaceutical company is material to investors assessing the company's medical and clinical capabilities.","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34113,"accession_number":"0001193125-26-380171","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Fawzi Benzaghou, the Company's Chief Medical Officer, is departing effective September 30, 2026, pursuant to a mutual agreement. While the disclosure mentions severance benefits, the principal disclosed action is the departure of a named executive officer from a key leadership position (CMO), making this an exec_departure event. The departure of a CMO at a biopharmaceutical company is material to investors assessing the company's medical and clinical capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:06:41.478827+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34113,"accession_number":"0001193125-26-380171","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Fawzi Benzaghou, the Company's Chief Medical Officer, is departing effective September 30, 2026, pursuant to a mutual agreement. While the disclosure mentions severance benefits, the principal disclosed action is the departure of a named executive officer from a key leadership position (CMO), making this an exec_departure event. The departure of a CMO at a biopharmaceutical company is material to investors assessing the company's medical and clinical capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:06:41.478827+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-09-02"}]}